针对慢性肺部阿斯伯吉洛症的优化抗真菌疗法
Yusuke Yagi1,2, Yuka Yamagishi2,3, Yukihiro Hamada1
1Department of Pharmacy, Kochi Medical School Hospital.
Medical mycology journal
|September 1, 2024
概括
慢性肺阿斯伯吉洛症 (CPA) 需要长期的抗真菌治疗. 新的药物,如 isavuconazole 提供更好的有效性和安全性,用于管理这种真菌性肺部感染.
科学领域:
- 医学真菌学 医学真菌学
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
背景情况:
- 慢性肺性阿斯伯吉洛症 (CPA) 涉及Aspergillus hyphae在免疫功能低下的个体中的扩散.
- 长期的全身抗真菌疗法是主要的治疗方法,而手术只适用于罕见的侵入性形式.
- 优化具有良好的药理动力学的抗真菌剂对于长期CPA管理至关重要.
研究的目的:
- 根据指南,审查CPA的抗真菌剂.
- 讨论适合CPA治疗的药物特征.
- 突出Isavuconazole作为一个新的治疗选择.
主要方法:
- 对抗真菌剂的文献审查和CPA的指导方针.
- 对抗真菌药物的药理动力学和安全性分析.
- 专注于第二代三醇,包括 isavuconazole.
主要成果:
- 现有的抗真菌药具有局限性;第二代三醇提供更广泛的谱和配方选择.
- 伊萨夫可纳证明了对阿斯伯吉卢斯的有效性,具有有利的安全性和药理动力学.
- 预计日本ISAVUCONAZOLE的可用性将扩大治疗策略.
结论:
- 伊萨夫可纳是侵入性真菌感染的有希望的选择,包括CPA.
- 适当的抗真菌选择,监测和耐药性评估是有效CPA治疗的关键.
- 新的证据将进一步完善CPA的治疗方法.
更多相关视频
相关概念视频
Pulmonary Tuberculosis V
174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
Cystic Fibrosis: Management
146
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
146
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Pneumonia IV: Management
311
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
311
Pulmonary Tuberculosis I
227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227


